Podcasts about GSK

This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease risk: Framingham Heart Study insights Sudden death in female athletes Mythbusters: Owning a pet reduces the risk of heart disease Host: Susanna Price Guests: Carlos Aguiar, Sabiha Gati, Vasan Ramachandran Want to watch that episode? Go to: https://esc365.escardio.org/event/1809 Want to watch that extended interview on sudden death in athletes? Go to: https://esc365.escardio.org/event/1809?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. The ESC is not liable for any translated content of this video.The English-language always prevails. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel, Susanna Price and Vasan Ramachandran have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Sabiha Gati Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1809?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1809   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Neste episódio especial da série: Precisamos Falar sobre HIV, uma parceria da GSK com o Estadão Blue Studio, o médico infectologista Dr. Vinícius Borges — mais conhecido como Dr. Maravilha — conduz uma conversa direta, acessível e atualizada sobre HIV, prevenção e saúde sexual. Com ênfase nas novas possibilidades de prevenção, como a PrEP (Profilaxia Pré-Exposição), o Dr. Maravilha explora o que há de mais moderno em estratégias de cuidado e autonomia. Informação de qualidade, sem tabu. Dê o play e venha entender o que sua saúde sexual tem a ver com tudo isso.See omnystudio.com/listener for privacy information.

In deze podcast, mede mogelijk gemaakt door AstraZeneca en Beigene, spreekt wetenschapsjournalist Judith Cohen met prof. dr. Stephan Stilgenbauer (Universiteit Ulm, Duitsland) over de huidige eerstelijnsbehandelopties voor patiënten met CLL. Aan bod komen de belangrijkste punten van de meest recente richtlijnupdates en zijn ervaring met de behandeling van CLL-patiënten.Disclosures Prof. dr. Stephan Stilgenbauer: AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson&Johnson, Lilly, Novartis, Sunesis.

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Join expert nurse practitioners Drs. Ruth Carrico and Audrey Stevenson on this engaging podcast episode as they illuminate the critical importance of respiratory syncytial virus (RSV) vaccination for adults. Learn actionable strategies to boost RSV vaccine uptake, address health disparities and protect your most vulnerable patients from this serious respiratory illness. A participation code will be provided at the end of the podcast — make sure to write this code down. Once you have listened to the podcast and have the participation code, return to this activity in the AANP CE Center (aanp.org/cecenter). Click on the "Next Steps" button of the activity and: Enter the participation code that was provided. Complete the post test. Complete the activity evaluation. This will award your continuing education (CE) credit and certificate of completion. 1.25 CE will be available through June 30, 2026. This podcast was supported by an independent medical education grant from GSK. Download the clinical resource handout here: 101199-PCE-AANP-RSV-Vaccine-infographic

The EMJ GOLD podcast is back for a new season! In the first episode of season 10, the team are joined by Dheepa Chari, Vice President and Head of Global Scientific Communications, GSK, to discuss the past, present and future of scientific communications. Together, Dheepa and Isabel explore her journey from biostatistics to biopharma leadership — and the lessons learned along the way. They discuss what great science communication looks like, where it's heading next and why storytelling still matters in a digital-first world. Plus, expect practical insights on cross-functional collaboration and the growing role of AI. A little more on EMJ GOLD's guest… Dheepa Chari is the Vice President and Head of Global Scientific Communications at GSK. Here, she leads strategy and execution across Oncology, Vaccines, Specialty Care and General Medicine, driving innovation in how scientific narratives are delivered across channels. Before joining GSK in 2024, Dheepa held senior posts at Pfizer, Amgen and Novartis in both clinical and communications roles. Outside of work, Dheepa brings stories to life in a different way - as a singer-songwriter who regularly performs in New York City.

In the latest collaboration between ACRO and TransCelerate BioPharma, Cris McDavid (Senior Director, Global Clinical Operations, Parexel) and Tashan Mistree (Senior Director, Business Operations, Office of Chief Medical Officer, GSK) join this week's episode to discuss the impact of ICH E6(R3) from their different vantage points in the clinical research industry. They dive deeper into their experiences implementing the new guidance at their respective companies, the new opportunities that R3 has created in the partnership between CROs and sponsors, and how they envision the future state of R3 once industry has fully embraced the guidance. FIND ACRO & TRANSCELERATE'S ICH E6(R3) TOOLS & RESOURCES HERE: https://www.acrohealth.org/initiatives-hub/interpreting-ich-e6r3/ 

UK economic data last week highlighted renewed inflation pressures and persistent uncertainty. Food inflation hit a one-year high in May, rising 2.8% year-on-year. Kantar reported that grocery prices surged 4.1%, the highest in 15 months, driven by higher payroll taxes and minimum wage hikes. Business confidence slumped, with Confederation of British Industry (“CBI”) surveys showing sharp declines across services, as firms cited rising employment costs and tax burdens. The Bank of England (“BoE”) Governor, Andrew Bailey, urged caution on rate cuts, citing inflation uncertainty and trade risks, while Monetary Policy Committee (“MPC”) member Alan Taylor advocated for easing due to downside risks. Despite headwinds, Lloyds' business barometer rebounded to 50%, buoyed by Donald Trump's softened tariff stance and a US-UK trade deal. However, artificial intelligence (“AI”) disruption concerns mounted, with youth unemployment rising to 12.6%...Stocks featured:Auto Trader Group, GSK and M>o find out more about the investment management services offered by Walker Crips, please visit our website:https://www.walkercrips.co.uk/This podcast is intended to be Walker Crips Investment Management's own commentary on markets. It is not investment research and should not be construed as an offer or solicitation to buy, sell or trade in any of the investments, sectors or asset classes mentioned. The value of any investment and the income arising from it is not guaranteed and can fall as well as rise, so that you may not get back the amount you originally invested. Past performance is not a reliable indicator of future results. Movements in exchange rates can have an adverse effect on the value, price or income of any non-sterling denominated investment. Nothing in this podcast constitutes advice to undertake a transaction, and if you require professional advice you should contact your financial adviser or your usual contact at Walker Crips. Walker Crips Investment Management Limited is authorised and regulated by the Financial Conduct Authority (FRN: 226344) and is a member of the London Stock Exchange. Hosted on Acast. See acast.com/privacy for more information.

Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH Recorded on May 13, 2025 Aaron Gerds, MD, MS Associate Professor of Medicine Cleveland Clinic Lerner College of Medicine Case Western Reserve University School of Medicine Medical Director Case Comprehensive Cancer Center Clinical Research Office Cleveland, OH In this episode, Dr. Aaron Gerds from the Cleveland Clinic explores the intricacies of Myeloproliferative Neoplasms (MPNs), from diagnosis and monitoring to treatment goals and the latest therapeutic advances. Dr. Gerds discusses emerging therapies, the significance of clinical trials, strategies for managing side effects and long-term effects, and valuable resources for healthcare professionals, patients, and families. Tune in today for expert insights on MPNs! This episode is supported by GSK plc and Karyopharm Therapeutics.

After nearly two decades at GSK, Pascal Lestrate took a leap into Biotech, joining Vicebio as Chief Preclinical Science Officer. In this episode of Careers in Discovery, Pascal shares how the shift from big pharma to early-stage Biotech gave him a chance to return to hands-on science - and start with a blank page. We explore the pioneering work Vicebio is doing on multi-pathogen respiratory vaccines using molecular clamp technology, including how their approach could reduce the number of injections needed while improving vaccine stability and access in low-resource settings. Pascal also reflects on his rich and varied career, from molecular biology and immunology to regulatory affairs, quality systems, and digital transformation. Along the way, he shares lessons on navigating major career transitions, leading without deep technical expertise, and how curiosity, values, and a willingness to take up space have shaped his path.

"There is  more  and more money  going into podcasting advertising every year. Billions and billions now worldwide. So where is it?"Let's be honest—everywhere you turn, you're being told podcasting is a goldmine. Billions of dollars in ad revenue! Massive growth! Side hustle magic! But where is that money really going? Because it's not landing in your inbox—or mine.In this episode of Smarter Podcasting, I'm joined by the brilliant Charlotte Lewis-West, a podcast strategist with a background in broadcast journalism and over a decade working with brands like GSK, Microsoft and Unilever. She's also one of my favourite people to work with at Seven Million Bikes Podcasts.Together, we dig into the real value of podcasting—and why making money through ads and sponsorships isn't the only (or smartest) goal. Charlotte and I get honest about what we've seen in the industry: the hype, the empty promises, and the reality for both indie creators and big-name brands.Here's what we cover:Why most podcast ad money goes to massive networks and the same three sponsors (hello, BetterHelp)Why I've hit over 100,000 downloads and never once had a sponsor approach meWhy brands keep making the same mistakes when launching a show—and how to avoid themThe real return on investment: brand awareness, authority, networking, and trustWhy engagement rate matters more than total downloadsHow to use your podcast to build relationships, not just numbersHow you should actually handle sponsors if they do come knocking (and how not to sell out your voice)We also get into some hard truths about what makes a podcast successful. Spoiler: it's not going viral or chasing trends. It's consistency, knowing your audience, and delivering actual value—week after week.This isn't about crushing dreams. It's about saving you from wasting time, money, and energy on the wrong things—and helping you build a podcast that works for you and your business.Timestamps02:02 – Why I started Smarter Podcasting and what we've achieved03:46 – Charlotte breaks down where the podcast ad money really goes07:00 – Why most shows (even good ones) don't get sponsors09:52 – How many downloads I've had—and why that's not the whole story13:00 – The real reasons to start a podcast (hint: not for ad money)17:30 – The biggest mistakes brands make with podcasts20:10 – “Build it and they will come” is a lie22:32 – The indie podcaster dilemma: doing too much at once24:58 – Monetization beyond sponsorship: smarter ways to get ROI28:10 – What to look for in a sponsor—and how to avoid sounding fake30:45 – Why authentic ads win and scripts usually suckSend us a textThe Podcast Launch LabThe Podcast Makeover Sign up for Descript now! Need a stunning new logo for your brand? Or maybe a short animation?Whatever you need, you can find it on Fiverr.I've been using Fiverr for years for everything from ordering YouTube thumbnails, translation services, keyword research, writing SEO articles to Canva designs and more!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.A court has halted the Trump administration's plans to reduce and lay off employees in government agencies, citing a lack of authority. Meanwhile, a report called "Make American Healthy Again" criticizes pharmaceutical lobbying, GLP-1s, and vaccines. The report also addresses rising autism rates and over-medication of children. Bio-Rad is redefining antibody discovery with their Pioneer Antibody Discovery Platform.In other news, Merus' bispecific shows promise in head-and-neck cancer, while Congress narrowly passes a tax bill with changes to IRA penalties and negotiation exemptions for orphan drugs. The FDA vaccine advisors agree on a COVID-19 vaccine as a new framework looms, and GSK wins expansion for Nucala after an FDA delay. Lilly expresses concern as CMS leaves obesity drugs out of Medicare coverage, and Sanofi acquires Vigil for $470 million upfront. And that's all for today's updates in the pharmaceutical and biotech world. Stay tuned for more essential news in our next episode.

This episode covers: Cardiology This Week: A concise summary of recent studies The role of cardiac magnetic resonance in myocardial disease Air pollution and heart disease Statistics Made Easy: Quasi-experimental study designs Host: Rick Grobbee Guests: Carlos Aguiar, Steffen Petersen, Mark Miller Want to watch that episode? Go to: https://esc365.escardio.org/event/1806 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Mark Miller have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Steffen Petersen Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1806?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

On this week's AJ Bell Money & Markets podcast, Dan Coatsworth and Tom Sieber explore some big names on the UK and US stock market following a spate of corporate updates over the past week. They chat about Guinness maker Diageo, sausage roll giant Greggs, and a trio of American firms which have given us a fascinating insight into the state of the US consumer. [6:05] Marks & Spencer has laid out the potential hit to profits from its recent cyber-attack and it's a hefty sum. Dan has all the details and he talks to fund manager Ian Lance from Temple Bar Investment Trust to get a shareholder's perspective on the incident. [14:30] Hear about the new threat to Next and Dunelm as a US home furnishings giant prepares to make its UK debut. [21:15] Dan chats about an important development in the buy now, pay later industry [25:20] and why there is some relief for certain victims of scams. [29:20] Tom has a fascinating insight into the UK property market as more Americans look to move to the UK. [32:05]. Tom also talks about big moves in the cash savings market. [34:50] Finally, don't miss the second part of our interview with Edinburgh Investment Trust's Emily Barnard who explains how AstraZeneca differs from GSK, key achievements from both companies, and where they might go next. [37:30]

The turbulence that has come with the Trump administration's policies related to the U.S. biopharmaceutical industry is creating an opening for Europe to bolster its life sciences industry. On the latest BioCentury This Week podcast, BioCentury's editors look at how Europe can capitalize on staffing cuts at FDA and NIH and an uncertain policy environment to lure back talent to bolster regulatory agencies and biotech R&D engines and attract assets and partners from China.The editors also discuss two biotech deals driven by former leaders of BD at Roche, Biomarin's James Sabry and Sophie Kornowski at Boston Pharmaceuticals. Under the leadership of Sabry and CEO Alexander Hardy, Biomarin delivered its first takeout in a decade by acquiring Inozyme as it positions itself to take advantage of a regulatory and policy environment that they believe is favorable to their rare disease strategy. CEO Kornowski, meanwhile, executed on a plan to focus her company on a single liver disease asset that GSK acquired for $1.2 billion up front. Finally, BioCentury's editors discuss the management shake-up at obesity company Novo Nordisk, where Lars Fruergaard Jørgensen, the leader who spearheaded Novo Nordisk's transformation into a dominant player in obesity, is stepping down.Chan Zuckerberg Chicago Biohub is hosting an exclusive, invite-only reception on June 3 — the eve of BioCentury's Grand Rounds conference — gathering top voices in biotech innovation and investment to exchange bold ideas, spark new collaborations and channel the energy of Chicago's thriving innovation ecosystem. If you're interested in attending, please register here. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655964#biotech #biopharma #pharma #lifescience #politics #policy #law00:01 - Sponsor Message: Jeito Capital05:05 - European Biotech's Moment?19:00 - Boston Pharma, Biomarin Deals29:41 - Novo Nordisk CEOTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.At a recent U.S. Senate hearing, Health and Human Services Secretary was questioned about cuts being made to the department and his stance on endorsing the measles vaccine during a growing outbreak. The hearing was tense at times, with RFK Jr. firm on supporting the cuts but wavering on his stance on the MMR vaccine. AbbVie's ADC received accelerated approval for lung cancer treatment, FDA delays decision on Biohaven's application, and chaos ensues at the FDA's advisory committee planning office after workforce cuts. Sino Biological offers solutions for autoimmune disease research, with reagents for nearly 50 diseases. Novo Nordisk has invested $2.4 billion in a new oral obesity drug through a deal with Septerna, aiming to catch up with competitors in the oral weight loss space. AbbVie has committed $335 million upfront in a partnership with Adarx Pharmaceuticals for siRNA research, while GSK has abandoned a TIGIT therapy and instead acquired rights to a liver drug from Boston Pharmaceuticals for potential $2 billion deal. This news highlights the ongoing developments and investments in the pharmaceutical industry.

On this week's episode of the AJ Bell Money and Markets podcast Danni Hewson and Charlene Young take stock of which trade deals have been struck in the wake of Donald Trump's tariff policies and assess how markets and some of those big US stocks like Nvidia have performed.[2:09]   A week after the Bank of England cut its base rates they consider where interest rates are likely to go next and whether the cut has been passed on in the form of mortgage and savings rates. [11:58]  Latest data shows the UK labour market is showing further signs of strain but the weather's given consumer spending a boost with positive updates from Wickes, Marston's, On the Beach and Next. [18:27] Marks and Spencer has updated markets on the cyber-attack which is still preventing online deliveries from the high street stalwart but can it keep customers on side? [26:08]  Dan Coatsworth talks to Emily Barnard from Edinburgh Investment Trust about tariffs on the pharmaceutical sector and where AstraZeneca and GSK stand with weight-loss drugs [29:53]  And Tom Sieber from Shares Magazine has been talking to fund managers about the surprise retirement of investing legend Warren Buffett. [45:40]

Grab your earphones! Get ready to listen and learn!

En este episodio analizamos las claves del inicio de semana en los mercados: • Wall Street vuela tras tregua EE.UU.–China: Futuros al alza con $SPX +3.1%, $US100 +4% y $INDU +2.4%. EE.UU. y China acordaron reducir aranceles por 90 días: Washington bajará del 145% al 30% y Pekín del 125% al 10%. Las conversaciones en Suiza fueron calificadas como “productivas” y se creará un mecanismo de consultas para seguir negociando. El mercado también espera el CPI de abril mañana. • Acuerdo alivia guerra arancelaria: El pacto cubre la mayoría de tarifas recíprocas recientes. Ambas potencias mantendrán la pausa mientras discuten nuevos términos. Se evalúa una posible reunión en EE.UU., China o un país neutral. Las bolsas globales reaccionan con fuerza al anuncio. • Trump golpea a farmacéuticas con nueva orden: El presidente anunció una orden ejecutiva para reducir precios de medicamentos entre 30%-80%, alineándolos con estándares internacionales. $LLY -2.2%, $AMGN -2.6%, $MRK -2.4%, $PFE -3.3%. En Europa, $AZN -5% y $GSK -2.6%. El sector salud fue el más afectado en Asia. Un episodio donde la diplomacia comercial domina el panorama, pero también se encienden alarmas en el sector farmacéutico global.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA is planning to fully integrate AI into their decision-making process by June 30, with individual centers starting the rollout immediately. Sanofi has cut off its antibody partner, leading to an 80% reduction in headcount at IgM Biosciences. The FDA has faced delays, including missing review dates for GSK's Nucala. President Trump is expected to unveil a drug pricing plan on Monday that has been criticized by big pharma and patient groups. Lotte Biologics offers end-to-end services for ADC manufacturing in Syracuse, NY. Rallybio, Insitro, Shape, and Vor have all downsized their workforces.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DEN865. CME/AAPA credit will be available until April 24, 2026.Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DEN865. CME/AAPA credit will be available until April 24, 2026.Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Michele Brignole Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1805?r  Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DEN865. CME/AAPA credit will be available until April 24, 2026.Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DEN865. CME/AAPA credit will be available until April 24, 2026.Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DEN865. CME/AAPA credit will be available until April 24, 2026.Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DEN865. CME/AAPA credit will be available until April 24, 2026.Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DEN865. CME/AAPA credit will be available until April 24, 2026.Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Two companies, Beam Therapeutics and Verve Therapeutics, have developed lead candidates using a safer alternative to conventional CRISPR called base editing. Clinical results have been promising. FDA insiders are calling on FDA Commissioner Marty Makary to fight against agency politicization. The Trump administration, including HHS Secretary Robert F. Kennedy Jr., is accused of distorting and denying scientific truths and potentially censoring information.FDA action alerts include expansion bids for drugs by GSK and Merck. A new AI-powered solution called Generative AIPTP helps life sciences firms streamline clinical workflows. The FDA is rehiring travel staff as lapses begin to show.RFK Jr. is driving a wedge into vaccine conversations. WHO may add obesity drugs for adults to the essential medicines list. Various companies like Merck, GSK, and Roche present key data at AACR 2025.HHS will require placebo-controlled trials for all new vaccines in a radical departure from past practices. Tariffs dominate Q1 earnings, AACR excites the cancer space, CEO pay gaps are discussed, and more news and events are highlighted.

En este episodio, repasamos los temas más importantes del día: • Wall Street celebra resultados tech: Los futuros suben con fuerza tras sólidos earnings de $MSFT (+8.2% premarket) y $META (+6.2%). $SPX +1.2%, $US100 +1.6% y $INDU +0.7%. Wall Street cerró con rebote tras la primera contracción del PIB desde 2022. Hoy se esperan datos de desempleo (224K), PMI e ISM de abril. • Trump impulsa vacuna universal: La administración lanza el programa “Generation Gold Standard” con $500B para desarrollar vacunas contra múltiples virus. Se usarán tecnologías clásicas como virus inactivados. Ensayos planeados para 2026; aprobación esperada en 2029. Involucra a $AZN, $GSK, $SNY, $PFE, $MRNA, $NVAX y otras. • Amazon amplía cobertura rural: $AMZN invertirá $4B en expandir su red de entregas en zonas rurales, cubriendo 13,000 códigos postales y creando 100,000 empleos. La iniciativa permitirá más de mil millones de paquetes adicionales al año. Acciones suben +2.7% tras el anuncio. Un episodio que destaca innovación médica, expansión logística y el poder de las tecnológicas en el mercado. ¡Dale play y no te lo pierdas!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis recently acquired Regulus for $1.7 billion, signaling a trend of increased M&A activity in the pharmaceutical industry. Many companies have hinted at upcoming deals during recent earnings calls, which is seen as a positive sign for the biopharma ecosystem amidst challenges like tariffs and potential drug pricing pressures. GSK remains optimistic about M&A opportunities despite the threat of tariffs, with CEO Emma Walmsley emphasizing a cautious and disciplined approach to dealmaking. Trilink Biotechnologies has introduced custom sets of mRNA for screening studies, offering flexibility and scalability for research needs. The AACR 2025 conference featured promising data from Marengo and Briacell, while Pfizer CEO Albert Bourla has been lobbying against pharmaceutical industry tariffs proposed by President Trump. Overall, the industry is seeing a mix of challenges and opportunities, with companies navigating trade tensions and economic uncertainties while also pursuing strategic growth through acquisitions and innovative research initiatives.Pharmaceutical companies are navigating political uncertainties, particularly in relation to tariffs and dealmaking with China. Major companies are investing billions in US manufacturing to avoid tariffs threatened by President Trump. Despite lobbying efforts, Trump has expressed national security concerns regarding the pharmaceutical industry. CEO-to-employee pay gaps in the industry remain significant. Novartis, GSK, and AstraZeneca are facing challenges and making strategic shifts in response to political and market conditions. Tariff uncertainty is impacting Q1 earnings, with companies like Merck taking significant financial hits. Despite these challenges, the industry remains active with mergers and acquisitions. Upcoming events and job opportunities in the biopharma sector are highlighted.

US President Trump said he is going to make a fair deal with China on trade; predicts that China will eat the tariffs.APAC stocks failed to sustain the positive handover from Wall St and traded mixed; Chinese official PMIs disappointed.European equity futures indicate a contained cash market open with Euro Stoxx 50 future flat after the cash market closed with losses of 0.2% on Tuesday.DXY is a touch higher and building on yesterday's slight gains, EUR/USD is back on a 1.13 handle, AUD leads post-CPI.Looking ahead, highlights include French GDP, German Import Prices, Retail Sales, Unemployment Rate, GDP, CPI, Italian GDP, CPI, EZ GDP, US ADP, GDP, PCE (Q1 & for March), ECI, BoC Minutes, BoE's Lombardelli, Supply from UK, Germany & US.Earnings from Microsoft, Meta, Robinhood, Qualcomm, Albemarle, eBay, Humana, Caterpillar, International Paper, GE Healthcare, Hess, Airbus, Credit Agricole, TotalEnergies, SocGen, UBS, DHL, Kion, Volkswagen, Mercedes Benz, Barclays, GSK, Segro & Glencore.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

As AI becomes a more integrated part of our daily lives, it is vital that we consider all stakeholder perspectives to enable us to better foster collaboration for effective AI integration in scientific publishing. In this episode we will explore AI's transformative impact on the creation and dissemination of scientific content, addressing the real-world challenges and diverse perspectives needed to harness its full potential. By considering the opportunities and barriers  (real and perceived) to AI adoption, we can distinguish how these challenges vary among stakeholders from a pharma, publisher, and patient advocate perspective. . Joining us for this conversation is Stephen Griffiths, Publications Head at GSK; Stephanie Preuss, Director of Content Innovation at Springer Nature; and Stephen Rowley, Patient Advocate and Director at Artension.To join ISMPP, visit our website at https://www.ismpp.org/ This episode is generously sponsored by Avalere Health.

In 2017 Emma Walmsley became the most powerful woman in corporate Britain. The boss of the drugmaker GSK says leadership is about clearly communicating the what, why and how of your company, and aligning your employees' incentives accordingly. Boss Class season one is free for a limited time. Season two will appear weekly starting May 12th. To hear new episodes, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

We love to hear from our listeners. Send us a message. On today's episode I'm speaking with Brian Lortie, President and CEO of Uniquity Bio, about his "no jerk" policy and how his experience building teams at GSK, Endo Pharmaceuticals, and Onspira Therapeutics informs his leadership at Uniquity, a clinical-stage immunology startup backed by Blackstone Life Sciences. Lortie also walks through the formation and launch of Uniquity and provides detail on the company's business model and strategy.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In 2017 Emma Walmsley became the most powerful woman in corporate Britain. The boss of the drugmaker GSK says leadership is about clearly communicating the what, why and how of your company, and aligning your employees' incentives accordingly. Boss Class season one is free for a limited time. Season two will appear weekly starting May 12th. To hear new episodes, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

Join us on the latest episode, hosted by Jared S. Taylor!Our Guest: Peter Donnelly, CEO & Co-Founder at Genomics.What you'll get out of this episode:Genomics' Mission: Founded in 2014, Genomics is bridging cutting-edge genetic research with real-world healthcare solutions.Actionable Insights: Advances now allow actionable health insights for ~70% of people via genetic testing.Strategic Partnerships: Collaborations with companies like Vertex and GSK use genetics to improve drug targeting and trial outcomes.Insurance Innovation: Life insurers are early adopters of genetics to promote longevity and healthier lives.The Future Is Now: With global health systems under pressure, predictive genomics is primed to shift care from treatment to prevention.To learn more about Genomics:Website: http://www.genomics.com/ LinkedIn: https://www.linkedin.com/company/genomics-ltd/Our sponsors for this episode are:Sage Growth Partners https://www.sage-growth.com/Quantum Health https://www.quantum-health.com/Show and Host's Socials:Slice of HealthcareLinkedIn: https://www.linkedin.com/company/sliceofhealthcare/Jared S TaylorLinkedIn: https://www.linkedin.com/in/jaredstaylor/WHAT IS SLICE OF HEALTHCARE?The go-to site for digital health executive/provider interviews, technology updates, and industry news. Listed to in 65+ countries.